May 8 (Reuters) - Teva Pharmaceuticals and partner Medincell said on Wednesday their experimental schizophrenia drug had met its main goal in a late-stage study. (Reporting by Puyaan Singh; Editing by Devika Syamnath)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.98 EUR | +0.63% | -1.96% | -3.85% |
Dec. 13 | Eutelsat: delisted from the SBF 120 and CAC Mid 60 indices | CF |
Dec. 13 | Euroapi: delisted from the SBF 120 and CAC Mid 60 indices | CF |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
21.68USD | -0.50% | -1.09% | 24.6B | ||
15.98EUR | +0.63% | -1.96% | 491M | ||
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MEDCL Stock
- News MedinCell S.A.
- Teva and Medincell's schizophrenia drug meets main goal of late-stage study